USPTO serial 98478168
GENTIBIO
Reviewed by CopyMark Law Group
Status 731Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- HANNAH, JESSICA L
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with GENTIBIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $474*
Plus Government fees of $375
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Cambridge, MA, US
Cambridge, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John V. Hobgood, Esquire
John V. Hobgood, Esquire Wilmer Cutler Pickering Hale and Dorr LLP60 State StreetBoston, MA 02109United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders, allergic diseases and disorders, autoimmune diseases and disorders, acute illness, diabetes, stroke, inflammation and inflammatory disease, respiratory and infectious diseases, acute respiratory distress illness, immunological disorders and metabolic diseases; Autologous therapies, namely, cells for medical purposes; Allogeneic therapies, namely, cells for medical purposes; Biological preparations for the treatment of cancer, namely, virotherapies; Human cells for medical purposes; Cells for medical therapy use; Cultured human cells for medical therapeutic use | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals and therapies, namely, drugs for autoimmune, alloimmune, and inflammatory diseases, for others; Custom manufacturing of biological cells; Consultation in the field of custom manufacture of pharmaceuticals, therapies, namely, drugs for autoimmune, alloimmune, and inflammatory diseases and biological cells | ACTIVE | — |
| 042 | Scientific research; Pharmaceutical and medical therapeutic research services; Medical research; Engineering of biological cells; Genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 23, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 22, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 22, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 22, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 23, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 22, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 22, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 22, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 22, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 25, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 25, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 19, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 31, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 6, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 6, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 6, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 19, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 19, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 19, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 12, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 4, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 1, 2024 | NWAP | NEW APPLICATION ENTERED | — |